



AQUA BIO TECHNOLOGY ASA

## Aqua Bio Technology ASA: Private Placement - Extension of Application Period

10.3.2025 08:55:05 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Reference is made to the stock exchange announcements from Aqua Bio Technology ASA ("**ABTEC**" or the "**Company**", and together with its consolidated subsidiaries, the "**Group**") on 7 March 2025 regarding the launch of a conditional private placement (the "**Private Placement**") of new shares (the "**New Shares**") in the Company.

The Company's Board of Directors have now resolved to extend the application period in the Private Placement until 11 March 2025 at 08.00 CET. The Board of Directors reserves the right to shorten or extend the application period in the Private Placement at any time and for any reason.

Subject to the application period being closed on 11 March 2025 at 08.00 CET, the extension implies that notifications of conditional allocation are expected to be sent on or about 11 March 2025 and that the extraordinary general meeting to discuss and vote over the share capital increases pertaining to the Private Placement and the potential Subsequent Offering will be held on or about 7 April 2025.

For further information, please contact

Fredrik Henriksen, CEO

Phone +47 900 20 078

\* \* \*

This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.

The stock exchange announcement was published by Jan Varming on the time and date provided.

### IMPORTANT INFORMATION

This announcement is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this announcement may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not

constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful absent registration, or an exemption from registration or qualification under the securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or indirectly, Australia, Canada, Japan, Hong Kong or the United States or any other jurisdiction in which such release, publication or distribution would be unlawful, and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States or to publications with a general circulation in the United States of America.

This announcement is not an offer for sale of securities in the United States. Securities may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Company does not intend to register any part of the offering in the United States or to conduct a public offering in the United States of the shares to which this document relates.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company.

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise.

### **Disclosure regulation**

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

### **Contacts**

- Fredrik Henriksen, CEO, Aqua Bio Technology ASA, +47 90 02 00 78, [fredrik.henriksen@aguabiotech.no](mailto:fredrik.henriksen@aguabiotech.no)

### **About Aqua Bio Technology ASA**

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

### **Attachments**

- [Download announcement as PDF.pdf](#)